Table 2. Characteristics of the study population by p53/L1CAM status.
| p53/L1CAM | ||||||
|---|---|---|---|---|---|---|
| p53wt/L1CAMneg | p53wt/L1CAMpos | p53ab/L1CAMneg | p53ab/L1CAMpos | Total | p value | |
| N (%) | 59 (13.6%) | 51 (11.7%) | 143 (32.9%) | 182 (41.8%) | 435 (100.0%) | |
| Age (SD) | 63.9 (10.836) | 64.0 (9.056) | 64.7 (12.943) | 67.9 (11.301) | 65.8 (11.680) | 0.016 |
| Race | ||||||
| Caucasian | 27 (45.8%) | 20 (39.2%) | 61 (42.7%) | 80 (44.0%) | 188 (43.2%) | 0.908 |
| Non-Caucasian | 32 (54.2%) | 31 (60.8%) | 82 (57.3%) | 102 (56.0%) | 247 (56.8%) | |
| PS | ||||||
| 0 | 15 (25.9%) | 14 (27.5%) | 41 (29.1%) | 38 (21.5%) | 108 (25.3%) | 0.917 |
| 1 | 38 (65.5%) | 32 (62.7%) | 84 (59.6%) | 121 (68.4%) | 275 (64.4%) | |
| 2 | 4 (6.9%) | 3 (5.9%) | 12 (8.5%) | 14 (7.9%) | 33 (7.7%) | |
| 3 | 1 (1.7%) | 2 (3.9%) | 4 (2.8%) | 4 (2.3%) | 11 (2.6%) | |
| Type of surgery | ||||||
| TAH | 1 (1.7%) | 1 (2.0%) | 5 (3.5%) | 5 (2.8%) | 12 (2.8%) | 0.622 |
| TAH + BSO | 15 (25.4%) | 11 (21.6%) | 40 (28.0%) | 58 (32.0%) | 124 (28.6%) | |
| TAH + BSO + LN | 23 (39.0%) | 23 (45.1%) | 50 (35.0%) | 51 (28.2%) | 147 (33.9%) | |
| TAH + BSO + LN + Omentectomy | 20 (33.9%) | 16 (31.4%) | 48 (33.6%) | 67 (37.0%) | 151 (34.8%) | |
| Histology | ||||||
| ECG3 | 24 (40.7%) | 14 (27.5%) | 60 (42.0%) | 35 (19.2%) | 133 (30.6%) | <0.001 |
| Serous | 4 (6.8%) | 6 (11.8%) | 20 (14.0%) | 77 (42.3%) | 107 (24.6%) | |
| Clear cell | 5 (8.5%) | 11 (21.6%) | 14 (9.8%) | 14 (7.7%) | 44 (10.1%) | |
| Carcinosarcoma | 11 (18.6%) | 3 (5.9%) | 25 (17.5%) | 21 (11.5%) | 60 (13.8%) | |
| Mixed | 13 (22.0%) | 16 (31.4%) | 24 (16.8%) | 35 (19.2%) | 88 (20.2%) | |
| SOE | 2 (3.4%) | 1 (2.0%) | 0 (0.0%) | 0 (0.0%) | 3 (0.7%) | |
| FIGO stage | ||||||
| I | 35 (59.3%) | 20 (39.2%) | 73 (51.0%) | 65 (35.7%) | 193 (44.4%) | 0.019 |
| II | 6 (10.2%) | 10 (19.6%) | 20 (14.0%) | 20 (11.0%) | 56 (12.9%) | |
| III | 12 (20.3%) | 14 (27.5%) | 35 (24.5%) | 70 (38.5%) | 131 (30.1%) | |
| IV | 6 (10.2%) | 7 (13.7%) | 15 (10.5%) | 27 (14.8%) | 55 (12.6%) | |
| Myometrial invasion | ||||||
| <50% | 31 (52.5%) | 23 (45.1%) | 77 (53.8%) | 89 (48.9%) | 220 (50.6%) | 0.678 |
| >50% | 28 (47.5%) | 28 (54.9%) | 66 (46.2%) | 93 (51.1%) | 215 (49.4%) | |
| Treatment | ||||||
| Observation | 16 (27.1%) | 7 (13.7%) | 36 (25.4%) | 37 (20.3%) | 96 (22.1%) | 0.055 |
| CT with/without RT | 24 (40.7%) | 31 (60.8%) | 61 (43.0%) | 105 (57.7%) | 221 (50.9%) | |
| RT and/or BT | 19 (32.2%) | 13 (25.5%) | 45 (31.7%) | 40 (22.0%) | 117 (27.0%) | |
| Relapse | ||||||
| No | 46 (78.0%) | 33 (64.7%) | 88 (61.5%) | 81 (44.8%) | 248 (57.1%) | <0.001 |
| Yes | 13 (22.0%) | 18 (35.3%) | 55 (38.5%) | 100 (55.2%) | 186 (42.9%) | |
| Site of relapse | ||||||
| Pelvic | 4 (30.8%) | 4 (22.2%) | 21 (38.2%) | 29 (29.0%) | 58 (31.2%) | 0.701 |
| Abdominal | 5 (38.5%) | 5 (27.8%) | 12 (21.8%) | 24 (24.0%) | 46 (24.7%) | |
| Distant | 4 (30.8%) | 9 (50.0%) | 22 (40.0%) | 47 (47%) | 82 (44.1%) | |
| Death | ||||||
| No | 43 (72.9%) | 27 (52.9%) | 64 (44.8%) | 57 (31.3%) | 191 (43.9%) | <0.001 |
| Yes | 16 (27.1%) | 24 (47.1%) | 79 (55.2%) | 125 (68.7%) | 244 (56.1%) | |
Abbreviations: SD, standard deviation; TAH, total abdominal hysterectomy; BSO, bilateral salpingoophorectomy; LN, lymphadenectomy; ECG3, endometrioid carcinoma grade 3; CT, adjuvant chemotherapy; RT, adjuvant radiotherapy; BT, adjuvant brachytherapy